Nachrichten und Videos - SOSEI CO LTD. SOLTF - Englisch - Seite 4

TOKYO and CAMBRIDGE, United Kingdom, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) announces its President & CEO Chris Cargill will present at the 41 st Annual J.P. Morgan Healthcare Conference. The presentation will take place in-person at the JW Marriott Hotel, San Francisco Union Square, and via webcast at 1:30pm Pacific Standard Time on Wednesday, 11 January 2023. An audio link to the Company’s webcast presentation can be accessed here ....

New agreement leverages Sosei Heptares’ GPCR-focused structure-based drug design capabilities and Lilly’s extensive development, commercialization and therapeutic area expertise Sosei Heptares eligible to receive US$37 million upfront in cash and further development and commercial milestone payments totalling up to US$694 million plus tiered royalties TOKYO and CAMBRIDGE, United Kingdom, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) announces it has...

TOKYO and CAMBRIDGE, United Kingdom, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, announces that it has reached an important R&D milestone under its discovery collaboration with AbbVie, the global biopharmaceutical company, focused on inflammatory and autoimmune diseases. The achievement triggers a payment of US$10 million to Sosei...

Agreements build on Sosei Heptares’ Target Identification and Validation strategy and translational medicine approach to drug discovery, enabling the Company to rapidly prioritize disease-relevant GPCR targets for structure-based drug design TOKYO and CAMBRIDGE, United Kingdom, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, announces it...

TOKYO and CAMBRIDGE, United Kingdom, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and first nine months ended 30 September 2022. The full report can be found here . Chris Cargill, President and CEO of Sosei Heptares, commented: “We have made exciting progress during the third quarter of 2022, building on the strategic and operational initiatives we...

TOKYO and CAMBRIDGE, United Kingdom, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) announces its President & CEO Chris Cargill and Matt Barnes, Head of UK R&D, will participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference on Tuesday, 15 November at 11:30 a.m. GMT / 6:30 a.m. ET / 8:30 p.m. JST. The live webcast of the ‘Fireside Chat’ will be available here . The replay will also be available at the same link for 90 days...

NBI-1117568 is an Investigational, First-in-Class, Muscarinic M4 Selective Agonist TOKYO and CAMBRIDGE, United Kingdom, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, notes its partner Neurocrine Biosciences Inc. (“Neurocrine”) announced the first patient has been randomized for its Phase 2 placebo-controlled, inpatient clinical study...

TOKYO and CAMBRIDGE, United Kingdom, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) will hold an R&D Day on Thursday, 13 October 2022, at 3:30 pm JST. The meeting will be held in person in Tokyo for institutional investors, securities analysts and the press and will also be available via a live webcast. Please click here to register for the event. Date: Thursday, 13 October 2022 Time: 3:30 pm – 5:30 pm JST (7:30 am – 9:30 am BST) Presenters: Chris...

TOKYO and CAMBRIDGE, United Kingdom, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR-focused structure-based drug design (SBDD) and development, is pleased to announce it has won Licensing Deal of the Year and Executive of the Year at the first Informa Pharma Intelligence Awards Japan held yesterday in Tokyo. The Informa Pharma Intelligence Awards Japan, the Japanese rendition of the...

TOKYO, Japan and CAMBRIDGE, United Kingdom, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2022. The full report can be found by clicking here . Chris Cargill, President and CEO of Sosei Heptares, commented: “The first half of 2022 has been an exciting period for Sosei Heptares. Our new leadership team has settled in...

Neurocrine to conduct placebo-controlled Phase 2 study to investigate NBI-1117568 (formerly HTL-0016878) as a potential new treatment for schizophrenia Clinical development milestone triggers payment of US$30 million to Sosei Heptares from Neurocrine NBI-1117568 is the most advanced candidate under the multi-program muscarinic receptor agonist collaboration between Sosei Heptares and Neurocrine TOKYO and CAMBRIDGE, United Kingdom, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the...

New strategic collaboration leverages Sosei Heptares’ StaR ® technology and SBDD platform and AbbVie’s extensive neuroscience expertise Second collaboration with AbbVie follows 2020 agreement focused on inflammatory and autoimmune diseases Sosei Heptares eligible to receive up to $80 million in upfront and near-term milestone payments and has potential to receive further downstream payments totalling up to US$1.2 billion, plus tiered royalties TOKYO, Japan and CAMBRIDGE, United Kingdom,...

TOKYO, Japan and LONDON and CAMBRIDGE, United Kingdom, July 22, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR 1 -focused structure-based drug design (SBDD) and development, and Cancer Research UK, the world’s largest private funder of cancer research, today announce the signing of an agreement to bring Sosei Heptares’ cancer immunotherapy drug candidate into a first-in-human trial. Under...

TOKYO, Japan and CAMBRIDGE, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2022 on Wednesday, 10 August 2022. The Company will host a webinar presentation with Chris Cargill, President and CEO, Matt Barnes, President of Heptares Therapeutics and Head of UK R&D, and Hironoshin Nomura, CFO, at 5 pm JST (9 am BST) on Wednesday, 10 August...

TOKYO, Japan and CAMBRIDGE, United Kingdom, May 26, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, today announces it has expanded its UK R&D operations into a second site within Granta Park, Cambridge, to The Cori Building, previously occupied by Cancer Research UK. The requirement for additional R&D space is being driven by the Company’s strategy to...

Collaboration is part of Sosei Heptares’ Target Identification and Validation (TIV) strategy to leverage multiple sophisticated technologies that drive creation of new drug discovery programs in key therapeutic areas Kallyope, pioneers in drug discovery involving the gut-brain axis, will gain unique and valuable access to the Sosei Heptares' compound library for its industry-leading biology platform to identify potential GPCR targets and advance the development of new gastrointestinal...

TOKYO, Japan and CAMBRIDGE, United Kingdom, May 13, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2022. The full report can be found by clicking here . Chris Cargill, President and CEO of Sosei Heptares, commented: “Sosei Heptares is entering a new and exciting phase in 2022. We have made strong progress evolving our organic strategy and...

Key focus on enabling prioritization and rapid progression of pipeline programs through to clinical proof-of-concept, a key milestone for value creation Sosei Heptares will use the collaboration to ‘turbo charge’ its internal discovery and early clinical development strategy, and unlock the full potential of its world-leading GPCR-based drug discovery and development platform Weatherden is a pioneering clinical development consulting group trusted by biopharma, venture capital funds,...

New team focused on expanding its GPCR-focused structure-based drug design platform and enhancing translational medicine capabilities ‘Venture-like’ capital allocation approach to focus pipeline development through to Phase 1b/2a clinical proof of concept in patients, and optimize value generation Mid-term global expansion plans include drug discovery technology investments, licensing late-stage products for Japan, and strategic acquisitions Mr. Chris Cargill appointed as President and Chief...

TOKYO and CAMBRIDGE, United Kingdom, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2021. The full report can be found by clicking here . Shinichi Tamura, President and CEO of Sosei Heptares, commented: “We made excellent progress during 2021 achieving multiple milestones that further validate our world-leading GPCR and structure-based...